Our study demonstrated that serum CTGF levels were significantly higher in all patients with PF-ILD (IPF + F-ILDs) and in the post-COVID-19 group compared to healthy controls. This evidence concerns the gene CCN2 and idiopathic pulmonary fibrosis.